Literature DB >> 27605589

Development of Short-Form Versions of the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R): A Proof-of-Principle Study.

Matthew D Finkelman1, Niels Smits2, Ronald J Kulich3,4, Kevin L Zacharoff5, Britta E Magnuson6, Hong Chang7, Jinghui Dong8, Stephen F Butler5.   

Abstract

BACKGROUND: The Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) is a 24-item questionnaire designed to assess risk of aberrant medication-related behaviors in chronic pain patients. The introduction of short forms of the SOAPP-R may save time and increase utilization by practitioners.
OBJECTIVE: To develop and evaluate candidate SOAPP-R short forms.
DESIGN: Retrospective study.
SETTING: Pain centers.
SUBJECTS: Four hundred and twenty-eight patients with chronic noncancer pain.
METHODS: Subjects had previously been administered the full-length version of the SOAPP-R and been categorized as positive or negative for aberrant medication-related behaviors via the Aberrant Drug Behavior Index (ADBI). Short forms of the SOAPP-R were developed using lasso logistic regression. Sensitivity, specificity, and area under the curve (AUC) of all forms were calculated with respect to the ADBI using the complete data set, training-test analysis, and 10-fold cross-validation. The coefficient alpha of each form was also calculated. An external set of 12 pain practitioners reviewed the forms for content.
RESULTS: In the complete data set analysis, a form of 12 items exhibited sensitivity, specificity, and AUC greater than or equal to those of the full-length SOAPP-R (which were 0.74, 0.67, and 0.76, respectively). The short form had a coefficient alpha of 0.76. In the training-test analysis and 10-fold cross-validation, it exhibited an AUC value within 0.01 of that of the full-length SOAPP-R. The majority of external practitioners reported a preference for this short form.
CONCLUSIONS: The 12-item version of the SOAPP-R has potential as a short risk screener and should be tested prospectively.
© 2016 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  Chronic Pain; Opioids; Risk Stratification; SOAPP-R; Short Form; Substance Abuse

Mesh:

Substances:

Year:  2017        PMID: 27605589      PMCID: PMC6279303          DOI: 10.1093/pm/pnw210

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  28 in total

1.  On the sins of short-form development.

Authors:  G T Smith; D M McCarthy; K G Anderson
Journal:  Psychol Assess       Date:  2000-03

2.  Doctor and pharmacy shopping for controlled substances.

Authors:  Gretchen L Peirce; Michael J Smith; Marie A Abate; Joel Halverson
Journal:  Med Care       Date:  2012-06       Impact factor: 2.983

3.  Shortening the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R): A Proof-of-Principle Study for Customized Computer-Based Testing.

Authors:  Matthew D Finkelman; Ronald J Kulich; Kevin L Zacharoff; Niels Smits; Britta E Magnuson; Jinghui Dong; Stephen F Butler
Journal:  Pain Med       Date:  2015-07-14       Impact factor: 3.750

4.  Redesigning delivery of opioids to optimize pain management, improve outcomes, and contain costs.

Authors:  Alex Cahana; Elizabeth J Dansie; Brian R Theodore; Hilary D Wilson; Dennis C Turk
Journal:  Pain Med       Date:  2012-12-28       Impact factor: 3.750

5.  Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history.

Authors:  Edward Michna; Edgar L Ross; Wilfred L Hynes; Srdjan S Nedeljkovic; Sharonah Soumekh; David Janfaza; Diane Palombi; Robert N Jamison
Journal:  J Pain Symptom Manage       Date:  2004-09       Impact factor: 3.612

6.  Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R).

Authors:  Stephen F Butler; Kathrine Fernandez; Christine Benoit; Simon H Budman; Robert N Jamison
Journal:  J Pain       Date:  2008-01-22       Impact factor: 5.820

7.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

8.  Development and validation of the Current Opioid Misuse Measure.

Authors:  Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison
Journal:  Pain       Date:  2007-05-09       Impact factor: 6.961

9.  Do pain patients at high risk for substance misuse experience more pain? A longitudinal outcomes study.

Authors:  Robert N Jamison; Carol L Link; Lisa D Marceau
Journal:  Pain Med       Date:  2009-08-07       Impact factor: 3.750

10.  Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF.

Authors:  Dhanalakshmi Koyyalagunta; Eduardo Bruera; Carrie Aigner; Harun Nusrat; Larry Driver; Diane Novy
Journal:  Pain Med       Date:  2013-04-30       Impact factor: 3.750

View more
  3 in total

1.  Measurement versus prediction in the construction of patient-reported outcome questionnaires: can we have our cake and eat it?

Authors:  Niels Smits; L Andries van der Ark; Judith M Conijn
Journal:  Qual Life Res       Date:  2017-11-02       Impact factor: 4.147

Review 2.  Pain Management in Oncology Patients Amidst the Opioid Epidemic: How To Minimize Non-Medical Opioid Use.

Authors:  Michael Chahin; Sabrina Matosz; Irene Khalel; Silas Day; Amany Keruakous
Journal:  Cureus       Date:  2021-11-12

3.  Application of risk assessment tools to predict opioid usage after shoulder surgery.

Authors:  Laila H Khoury; Josh Stephens; Shimron Brown; Kiran Chatha; Sarah Girshfeld; Juan Manuel Lozano Leon; Alessia Lavin; Vani J Sabesan
Journal:  JSES Int       Date:  2022-07-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.